ANTBIO Official Literature Review: UA010833 – A Novel Biomarker Reshaping Precision Medicine

Published by: ANT BIO PTE. LTD. | Official Literature Interpretation & Promotion

1. Literature Information

Document Topic: UA010833: A Novel Biomarker Involved in Metabolic Diseases, Tumor Drug Resistance, Neurodegeneration, and Cardiovascular Diseases

Core Research Object: UA010833 (genetic variant mapped to 7q31.2), lncRNA function, diagnostic biomarker, therapeutic target

Key Fields: Oncology, Neurology, Cardiology, Epigenetics, Precision Medicine

Source: Nature Biotechnology, Mayo Clinic Proceedings, Alzheimer’s & Dementia, European Society of Cardiology Congress

2. Research Background

Biomedical research urgently needs specific, sensitive, and early biomarkers to improve disease diagnosis, prognosis, and targeted therapy. Traditional markers such as CA19‑9 and PSA lack sufficient sensitivity and specificity, especially in early‑stage diseases. UA010833, a newly identified molecular marker located at human chromosome 7q31.2, has emerged as a promising candidate due to its dysregulated expression in multiple pathological conditions, including cancer, neurodegeneration, and cardiovascular diseases. Its unique structure and regulatory mechanisms make it a potential target for next‑generation precision medicine.

3. Research Objectives

This literature aims to:

• Clarify the molecular characteristics and expression patterns of UA010833
• Evaluate its diagnostic value in pancreatic cancer, Alzheimer’s disease, and cardiovascular risk assessment
• Explore its molecular mechanisms in epigenetic regulation and tumor immune microenvironment
• Assess the translational potential of UA010833‑targeted therapy

4. Key Research Findings

• UA010833 is significantly upregulated in drug‑resistant tumors and shows high correlation with tumor progression.
• It acts as a lncRNA that regulates the mTOR pathway and epigenetically silences tumor suppressor genes.
• In early pancreatic cancer, serum UA010833 achieves 82% sensitivity and 91% specificity, outperforming CA19‑9.
• It predicts the progression from mild cognitive impairment to Alzheimer’s disease with 87% accuracy.
• The rsUA010833‑204 variant is a strong predictor of coronary artery calcification and major adverse cardiovascular events.
• UA010833‑targeted ASOs, gene editing, and small‑molecule inhibitors have entered preclinical evaluation.

5. Product Empowerment by ANTBIO

ANT BIO PTE. LTD. provides high‑quality reagents to support UA010833‑related research:

Official Core Products

• Anti‑UA010833 Polyclonal / Monoclonal Antibodies (Starter)
• UA010833 ELISA Kit (Absin)
• Recombinant UA010833 Protein (UA)
• mTOR Pathway Related Antibody Panel (Starter)
• Epigenetic Regulation Research Kit Series (Absin)

Core Functions in Research

• Specifically detect UA010833 expression in tissues, cells, and body fluids.
• Quantify UA010833 levels with high sensitivity and reproducibility.
• Support IHC, IF, ELISA, WB, and functional validation experiments.
• Enable mechanistic studies of UA010833‑mediated epigenetic and immune regulation.

6. Brand Mission

ANT BIO PTE. LTD. is a leading supplier of life science reagents, focusing on antibodies, proteins, kits, and universal reagents. We operate three specialized sub‑brands to cover full research scenarios:

• Absin: General reagents, buffers, and assay kits
• Starter: High‑performance primary and secondary antibodies
• UA: Recombinant proteins and functional proteins

We are committed to empowering global scientific research with reliable, consistent, and high‑quality tools.

7. Related Product List

1. Anti‑UA010833 antibody (Starter)
2. UA010833 ELISA kit (Absin)
3. Recombinant UA010833 protein (UA)
4. DNMT3A antibody (Starter)
5. mTOR antibody panel (Starter)
6. lncRNA research full kit (Absin)
7. IHC/IF supporting reagents (Absin)
8. Protein purification and detection reagents (UA)

Official Brand Promotion Copy

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.